ApoB

ApoB counts every atherogenic particle in your blood, LDL, IDL, VLDL, Lp(a), in a single measurement. Each of those particles carries exactly one apolipoprotein B molecule, so the ApoB concentration is a direct particle count rather than the cholesterol-mass estimate that LDL-C provides. In nearly every head-to-head comparison, ApoB is a stronger and more consistent cardiovascular risk predictor than LDL-C.

Optimal range

Range varies by individual.

Avg. cost (US)

$55

Test frequency

Annually; quarterly during active intervention

When to measure

Fasted 12 hours for accurate triglycerides (ApoB itself does not require fasting, but the panel typically does).

How to measure

Direct immunoassay or LC-MS. NMR LipoProfile gives ApoB-particle count alongside particle size.

Average cost

≈ $55 cash price. Often covered by insurance with relevant ICD-10.

Why this biomarker matters

Cumulative lifetime exposure to ApoB-containing particles is the single best-validated causal driver of atherosclerotic cardiovascular disease in humans. Genetic studies (Mendelian randomization across hundreds of thousands of participants) and pharmacologic studies (statins, ezetimibe, PCSK9 inhibitors, bempedoic acid) converge on the same conclusion: lower ApoB lowers cardiovascular events, and the relationship is linear down to the lowest measured values. ApoB matters more than LDL-C in two specific scenarios that affect a meaningful fraction of high-performing men. The first is discordant lipids: a normal-looking LDL-C of 100 mg/dL can hide an elevated ApoB of 110 mg/dL when small, dense LDL particles dominate, a pattern common in metabolic syndrome, insulin resistance, and high-protein low-carb dietary patterns. The second is on-treatment monitoring; once a statin shifts particle composition, ApoB tracks residual risk more faithfully than LDL-C. A reasonable target for primary prevention in longevity-focused men is ApoB under 80 mg/dL, with under 60 mg/dL for those with strong family history of early coronary disease or known Lp(a) elevation. The trial data consistently suggest lower is better within the ranges studied, with no clearly identified floor of benefit.